The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer

Basit Öğe Kaydı
dc.authoridCelik, Emir/0000-0001-8440-3082
dc.authoridOZGUROGLU, MUSTAFA/0000-0002-8417-8628
dc.contributor.authorCelik, Emir
dc.contributor.authorSamanci, Nilay Sengul
dc.contributor.authorKaradag, Mehmet
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorDemirelli, Fuat Hulusi
dc.contributor.authorOzguroglu, Mustafa
dc.date.accessioned2024-09-18T20:06:12Z
dc.date.available2024-09-18T20:06:12Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe objective of this study was to evaluate the efficacy and toxicity of capecitabine in metastatic breast cancer (mBC) according to the estimated glomerular filtration rate (eGFR). A total of 135 patients included in the final analysis were stratified into 3 categories according to baseline eGFR, i.e., eGFR <60 mL/min/1.73 m(2) (Group 1), eGFR 60-90 mL/min/1.73 m(2) (Group 2) and eGFR >90 mL/min/1.73 m(2) (Group 3). If a patient developed a level of toxicity that would lead to capecitabine dose reduction, this was recognized as dose-limiting toxicity (DLT). The dose was reduced due to toxicity in 95 cycles. A total of 95 DLTs were seen in 76 (56.2%) of the 135 patients. When 76 patients with DLT were evaluated according to eGFR, DLT was observed in 93.3% of those in Group 1, 72.5% of those in Group 2 and 41.3% of those in Group 3 (p < 0.001). The median time to progression (TTP) of all patients was 7.4 months. No significant difference in TTP was observed in patients stratified into 3 groups according to eGFR. When the patients were divided into two groups as DLT and without DLT, the median TTP was 8.68 months (95% CI, 7.53-9.81 months) in those with toxicity and 6.23 months (95% CI, 4.04-8.43 months) in those without toxicity (log-rank p = 0.004). We found a significant relationship between low eGFR and increased risk of DLT. Having a DLT was associated with a longer TTP. It indicates the need for more data/larger study investigating these discrepancies.en_US
dc.identifier.doi10.1007/s12032-021-01457-2
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue1en_US
dc.identifier.pmid33452614en_US
dc.identifier.scopus2-s2.0-85100109597en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-021-01457-2
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8371
dc.identifier.volume38en_US
dc.identifier.wosWOS:000609471000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectRenal insufficiencyen_US
dc.subjectCapecitabineen_US
dc.subjectToxicityen_US
dc.titleThe relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full text
Boyut:
743.42 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu